Antonios Matsakas

Dr. Antonios Matsakas

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HAHelge Amthor
Helge Amthor
AOAnthony Otto
Anthony Otto
AVAdeline Vulin
Adeline Vulin
ARAnne Rochat
Anne Rochat
JDJulie Dumonceaux
Julie Dumonceaux
TPTerence Partridge
Terence Partridge
Myostatin, a member of the TGF-β family, has been identified as a powerful inhibitor of muscle growth. Absence or blockade of myostatin induces massive skeletal muscle hypertrophy that is widely attributed to proliferation of the population of muscle fiber-associated satellite cells that have been identified as the principle source of new muscle tissue during growth and regeneration. Postnatal blockade of myostatin has been proposed as a basis for therapeutic strategies to combat muscle loss in genetic and acquired myopathies. But this approach, according to the accepted mechanism, would raise the threat of premature exhaustion of the pool of satellite cells and eventual failure of muscle regeneration. Here, we show that hypertrophy in the absence of myostatin involves little or no input from satellite cells. Hypertrophic fibers contain no more myonuclei or satellite cells and myostatin had no significant effect on satellite cell proliferation in vitro, while expression of myostatin receptors dropped to the limits of detectability in postnatal satellite cells. Moreover, hypertrophy of dystrophic muscle arising from myostatin blockade was achieved without any apparent enhancement of contribution of myonuclei from satellite cells. These findings contradict the accepted model of myostatin-based control of size of postnatal muscle and reorient fundamental investigations away from the mechanisms that control satellite cell proliferation and toward those that increase myonuclear domain, by modulating synthesis and turnover of structural muscle fiber proteins. It predicts too that any benefits of myostatin blockade in chronic myopathies are unlikely to impose any extra stress on the satellite cells.

1 October 2001 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
VMVassilis Mougios
Vassilis Mougios
Antonios MatsakasAntonios Matsakas
Antonios Matsakas
APAnatoli Petridou
Anatoli Petridou
SRSusanne Ring
Susanne Ring
ASAngelos Sagredos
Angelos Sagredos
MNMichalis Nikolaidis
Michalis Nikolaidis

1 July 2009 in Neuromuscular Disorders
Verified
Journal Article
Closed access
Antonios MatsakasAntonios Matsakas
Antonios Matsakas
KFKeith Foster
Keith Foster
AOAnthony Otto
Anthony Otto
RMRaymond Macharia
Raymond Macharia
MEMohamed Elashry
Mohamed Elashry
KPKetan Patel
Ketan Patel

1 June 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FSFrancesca Solagna
Francesca Solagna
CTCaterina Tezze
Caterina Tezze
MLMaja Lindenmeyer
Maja Lindenmeyer
SLShun Lu
Shun Lu
GWGuochao Wu
Guochao Wu
THTobias B. Huber
Tobias B. Huber
Skeletal muscle wasting is commonly associated with chronic kidney disease (CKD), resulting in increased morbidity and mortality. However, the link between kidney and muscle function remains poorly understood. Here, we took a complementary interorgan approach to investigate skeletal muscle wasting in CKD. We identified increased production and elevated blood levels of soluble pro-cachectic factors, including activin A, directly linking experimental and human CKD to skeletal muscle wasting programs. Single-cell sequencing data identified the expression of activin A in specific kidney cell populations of fibroblasts and cells of the juxtaglomerular apparatus. We propose that persistent and increased kidney production of pro-cachectic factors, combined with a lack of kidney clearance, facilitates a vicious kidney/muscle signaling cycle, leading to exacerbated blood accumulation and, thereby, skeletal muscle wasting. Systemic pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap as well as muscle-specific adeno-associated virus–mediated downregulation of its receptor ACVR2A/B prevented muscle wasting in different mouse models of experimental CKD, suggesting that activin A is a key factor in CKD-induced cachexia. In summary, we uncovered a crosstalk between kidney and muscle and propose modulation of activin signaling as a potential therapeutic strategy for skeletal muscle wasting in CKD.

18 June 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Antonios MatsakasAntonios Matsakas
Antonios Matsakas
VYVikas Yadav
Vikas Yadav
SLSabina Lorca
Sabina Lorca
Vihang A. NarkarVihang A. Narkar
Vihang A. Narkar
Treatment of Duchenne muscular dystrophy (DMD) by replacing mutant dystrophin or restoring dystrophin‐associated glycoprotein complex (DAG) has been clinically challenging. Instead, identifying and targeting muscle pathways deregulated in DMD will provide new therapeutic avenues. We report that the expression of nuclear receptor estrogen‐related receptor‐γ (ERRγ), and its metabolic and angiogenic targets are downregulated (50–85%) in skeletal muscles of mdx mice (DMD model) vs. wild‐type mice. Corelatively, oxidative myofibers, muscle vasculature, and exercise tolerance (33%) are decreased in mdx vs. wild‐type mice. Overexpressing ERRγ selectively in the dystrophic muscles of the mdx mice restored metabolic and angiogenic gene expression compared with control mdx mice. Further, ERRγ enhanced muscle oxidative myofibers, vasculature, and blood flow (by 33–66%) and improved exercise tolerance (by 75%) in the dystrophic mice. Restoring muscle ERRγ pathway ameliorated muscle damage and also prevented DMD hallmarks of postexercise muscle damage, hypoxia, and fatigue in mdx mice. Notably, ERRγ did not restore sarcolemmal DAG complex, which is thus dispensable for antidystrophic effects of ERRγ. In summary, ERRγ‐dependent metabolic and angiogenic gene program is defective in DMD, and we demonstrate that its restoration is a potential strategy for treating muscular dystrophy.—Matsakas, A., Yadav, V., Lorca, S., Narkar, V., Muscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming. FASEB J. 27, 4004–4016 (2013). www.fasebj.org

8 December 2011 in Experimental Physiology
Verified
Journal Article
Open access
PDF file
Antonios MatsakasAntonios Matsakas
Antonios Matsakas
RMRaymond Macharia
Raymond Macharia
AOAnthony Otto
Anthony Otto
MEMohamed Elashry
Mohamed Elashry
EMEtienne Mouisel
Etienne Mouisel
KPKetan Patel
Ketan Patel
Myostatin regulates both muscle mass and muscle metabolism. The myostatin null (MSTN−/−) mouse has a hypermuscular phenotype owing to both hypertrophy and hyperplasia of the myofibres. The enlarged muscles display a reliance on glycolysis for energy production; however, enlarged muscles that develop in the absence of myostatin have compromised force‐generating capacity. Recent evidence has suggested that endurance exercise training increases the oxidative properties of muscle. Here, we aimed to identify key changes in the muscle phenotype of MSTN−/− mice that can be induced by training. To this end, we subjected MSTN−/− mice to two different forms of training, namely voluntary wheel running and swimming, and compared the response at the morphological, myocellular and molecular levels. We found that both regimes normalized changes of myostatin deficiency and restored muscle function. We showed that both exercise training regimes increased muscle capillary density and the expression of Ucp3, Cpt1α, Pdk4 and Errγ, key markers for oxidative metabolism. Cross‐sectional area of hypertrophic myofibres from MSTN−/− mice decreased towards wild‐type values in response to exercise and, in this context, Bnip3, a key autophagy‐related gene, was upregulated. This reduction in myofibre size caused an increase of the nuclear‐to‐cytoplasmic ratio towards wild‐type values. Importantly, both training regimes increased muscle force in MSTN−/− mice. We conclude that impaired skeletal muscle function in myostatin‐deficient mice can be improved through endurance exercise‐mediated remodelling of muscle fibre size and metabolic profile.